Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S (NYSE:NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Novo Nordisk aims to generate annual obesity drug sales of more than DKK25 billion by 2025. Novo's diabetes and obesity sales leaped 15% to DKK121.6 billion in 2021. Obesity sales alone rose 55%. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.